Acute myeloid leukaemia: guideline history

Standard of care today →

4 dated versions from 2017 to 2025 listing 8 changes. Pick two versions to see what changed between them; the timeline below shows every version with the event it is anchored to.

From (exclusive)To (inclusive)

+3 added0 removed↔ 0 recategorisedacross 2 versions

Added
Newly diagnosed, fit, FLT3-ITD
Quizartinib with 7+3 as an alternative to midostaurin for FLT3-ITD (not TKD) disease.
Quizartinib Midostaurin QuANTUM-First
Added
Relapsed or refractory, KMT2A-rearranged
Revumenib, the first menin inhibitor, for relapsed or refractory KMT2A-rearranged acute leukaemia.
Revumenib AUGMENT-101
Added
Relapsed or refractory, NPM1-mutated
Ziftomenib for NPM1-mutated relapsed or refractory AML.
Ziftomenib KOMET-001

Timeline

2017-09NCCN2017 updates
Anchored to: FDA approvals of midostaurin (April 2017, RATIFY), CPX-351 (August 2017), enasidenib (August 2017) and the re-approval of gemtuzumab ozogamicin (September 2017, ALFA-0701)
- addedNewly diagnosed, fit, FLT3-mutated: Midostaurin added to 7+3 induction and consolidation.
- addedNewly diagnosed, therapy-related or secondary AML: CPX-351 (liposomal daunorubicin-cytarabine) in place of 7+3.
- addedNewly diagnosed, favourable-risk, CD33-positive: Gemtuzumab ozogamicin with induction chemotherapy.
2020-06ESMOESMO CPG acute myeloid leukaemia in adults 2020 (Heuser et al.)
Anchored to: Annals of Oncology publication, 2020
- addedNewly diagnosed, unfit for intensive chemotherapy: Venetoclax with azacitidine or low-dose cytarabine recommended over hypomethylating agent alone [I, A].
- addedRelapsed or refractory, FLT3-mutated: Gilteritinib recommended over salvage chemotherapy [I, A].
2023-07NCCN2023 update
Anchored to: FDA approval of quizartinib with induction and consolidation for FLT3-ITD AML, July 2023 (QuANTUM-First)
- addedNewly diagnosed, fit, FLT3-ITD: Quizartinib with 7+3 as an alternative to midostaurin for FLT3-ITD (not TKD) disease.
2025-11NCCN2024-2025 updates
Anchored to: FDA approvals of revumenib for KMT2A-rearranged acute leukaemia (November 2024, AUGMENT-101) and ziftomenib for NPM1-mutated AML (2025, KOMET-001)
- addedRelapsed or refractory, KMT2A-rearranged: Revumenib, the first menin inhibitor, for relapsed or refractory KMT2A-rearranged acute leukaemia.
- addedRelapsed or refractory, NPM1-mutated: Ziftomenib for NPM1-mutated relapsed or refractory AML.

Other cancers

Bladder & urothelial cancer Cervical cancer Chronic lymphocytic leukaemia Colorectal cancer Diffuse large B-cell lymphoma Endometrial cancer Gastric & gastro-oesophageal junction cancer Hepatocellular carcinoma HER2-positive breast cancer HR-positive / HER2-negative breast cancer Melanoma Multiple myeloma Non-small-cell lung cancer Oesophageal cancer Ovarian cancer Prostate cancer Renal cell carcinoma Triple-negative breast cancer (TNBC)

Each entry is anchored to a dated public event and links to the guideline body’s page for the disease; NCCN “Summary of changes” pages sit behind a free login and are not reproduced. Version labels say “update” where the NCCN version number has not been verified. Corrections are welcome via the repository.